TCR2 Therapeutics Inc.

NasdaqGS:TCRR Stock Report

Market Cap: US$58.1m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

TCR2 Therapeutics Management

Management criteria checks 3/4

TCR2 Therapeutics' CEO is Garry Menzel, appointed in Jan 2016, they has a tenure of 7.42 years. Their total yearly compensation is $1.74M , comprised of 34.5% salary and 65.5% bonuses, including company stock and options. They directly owns 1.03% of the company’s shares, worth $598.41K. The average tenure of the management team and the board of directors is 2.5 years and 3.8 years respectively.

Key information

Garry Menzel

Chief executive officer

US$1.7m

Total compensation

CEO salary percentage34.5%
CEO tenure7.4yrs
CEO ownership1.0%
Management average tenure2.5yrs
Board average tenure3.8yrs

Recent management updates

Recent updates

Here's Why TCR2 Therapeutics (NASDAQ:TCRR) Must Use Its Cash Wisely

Mar 08
Here's Why TCR2 Therapeutics (NASDAQ:TCRR) Must Use Its Cash Wisely

Can TCR2 Therapeutics (NASDAQ:TCRR) Afford To Invest In Growth?

Nov 23
Can TCR2 Therapeutics (NASDAQ:TCRR) Afford To Invest In Growth?

TCR² Therapeutics: Betting On A Solid Reversal

Aug 18

TCR2 Therapeutics GAAP EPS of -$0.82 misses by $0.02

Aug 08

We Think TCR2 Therapeutics (NASDAQ:TCRR) Needs To Drive Business Growth Carefully

Jun 08
We Think TCR2 Therapeutics (NASDAQ:TCRR) Needs To Drive Business Growth Carefully

We Think TCR2 Therapeutics (NASDAQ:TCRR) Can Afford To Drive Business Growth

Jan 11
We Think TCR2 Therapeutics (NASDAQ:TCRR) Can Afford To Drive Business Growth

TCR2 Therapeutics: Trading Below Cash

Jan 06

TCR2 Therapeutics: Trading Near Cash Value

Oct 12

Is There An Opportunity With TCR2 Therapeutics Inc.'s (NASDAQ:TCRR) 26% Undervaluation?

Sep 02
Is There An Opportunity With TCR2 Therapeutics Inc.'s (NASDAQ:TCRR) 26% Undervaluation?

TCR2 Therapeutics - Promising Technology And Upside Potential

Jun 15

Companies Like TCR2 Therapeutics (NASDAQ:TCRR) Are In A Position To Invest In Growth

Jun 04
Companies Like TCR2 Therapeutics (NASDAQ:TCRR) Are In A Position To Invest In Growth

Who Has Been Selling TCR2 Therapeutics Inc. (NASDAQ:TCRR) Shares?

Feb 19
Who Has Been Selling TCR2 Therapeutics Inc. (NASDAQ:TCRR) Shares?

TCR2 Therapeutics (NASDAQ:TCRR) Is In A Good Position To Deliver On Growth Plans

Dec 28
TCR2 Therapeutics (NASDAQ:TCRR) Is In A Good Position To Deliver On Growth Plans

TCR2 Therapeutics share slumps 11%, announces response for Phase 1/2 Trial of TC-210

Dec 14

TCR2 Therapeutics reports Q3 results

Nov 12

TCR² Therapeutics teams up with ElevateBio to expand TC-210 manufacturing capacity

Nov 10

CEO Compensation Analysis

How has Garry Menzel's remuneration changed compared to TCR2 Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2023n/an/a

-US$163m

Dec 31 2022US$2mUS$603k

-US$152m

Sep 30 2022n/an/a

-US$119m

Jun 30 2022n/an/a

-US$115m

Mar 31 2022n/an/a

-US$107m

Dec 31 2021US$2mUS$580k

-US$100m

Sep 30 2021n/an/a

-US$91m

Jun 30 2021n/an/a

-US$81m

Mar 31 2021n/an/a

-US$73m

Dec 31 2020US$6mUS$560k

-US$67m

Sep 30 2020n/an/a

-US$61m

Jun 30 2020n/an/a

-US$58m

Mar 31 2020n/an/a

-US$53m

Dec 31 2019US$8mUS$492k

-US$97m

Sep 30 2019n/an/a

-US$96m

Jun 30 2019n/an/a

-US$100m

Mar 31 2019n/an/a

-US$107m

Dec 31 2018US$3mUS$436k

-US$62m

Sep 30 2018n/an/a

-US$55m

Dec 31 2017US$792kUS$423k

-US$15m

Compensation vs Market: Garry's total compensation ($USD1.74M) is above average for companies of similar size in the US market ($USD752.41K).

Compensation vs Earnings: Garry's compensation has been consistent with company performance over the past year.

CEO

Garry Menzel (59 yo)

7.4yrs

Tenure

US$1,744,815

Compensation

Dr. Garry E. Menzel, Ph D., M.B.A. serves as an Independent Director at Black Diamond Therapeutics, Inc. since March 2017. He is a co-founder of Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical...

Leadership Team

NamePositionTenureCompensationOwnership
Garry Menzel
President7.4yrsUS$1.74m1.03%
$ 598.4k
Alfonso Cardama
Chief Medical Officer6.4yrsUS$1.01m0.28%
$ 162.0k
Rosemary Harrison
Chief Business & Strategy Officer1.4yrsUS$1.07m0%
$ 0
Patrick Baeuerle
Founder & Member of the Advisory Boardno dataUS$47.02kno data
Eric Sullivan
Chief Financial Officer1yrno datano data
Peter Olagunju
Chief Operating Officerless than a yearUS$2.74m0.061%
$ 35.7k
Carl Mauch
Senior Director of Investor Relations & Corporate Communicationsno datano datano data
Margaret Siegel
General Counsel5.4yrsno datano data
Angela Justice
Chief People Officer3.7yrsno data0.12%
$ 72.1k
Richard Roomberg
Vice President of Corporate Controller1.1yrsno datano data

2.5yrs

Average Tenure

49yo

Average Age

Experienced Management: TCRR's management team is considered experienced (2.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Garry Menzel
President7.4yrsUS$1.74m1.03%
$ 598.4k
Patrick Baeuerle
Founder & Member of the Advisory Board1.7yrsUS$47.02kno data
Ansbert Gadicke
Independent Director8.1yrsno datano data
Neil Gibson
Independent Director5.3yrsUS$68.42k0%
$ 0
Mitchell Finer
Chairman of Advisory Boardno dataUS$18.75k0%
$ 0
Stephen Webster
Independent Chairman of the Board3.1yrsUS$95.92k0%
$ 0
Andrew Allen
Independent Director4.5yrsUS$63.42k0%
$ 0
Axel Hoos
Independent Director3.2yrsUS$54.92k0%
$ 0
Shawn Tomasello
Independent Director2.3yrsUS$59.92k0%
$ 0
Kai Wucherpfennig
Member of Advisory Boardno datano datano data
Stephan Grupp
Member of the Advisory Boardno datano datano data
Wolfgang Schamel
Member of Advisory Boardno datano datano data

3.8yrs

Average Tenure

64yo

Average Age

Experienced Board: TCRR's board of directors are considered experienced (3.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/06/03 02:11
End of Day Share Price 2023/05/31 00:00
Earnings2023/03/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

TCR2 Therapeutics Inc. is covered by 12 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Clarence PowellBMO Capital Markets Equity Research
Guyn KimBMO Capital Markets Equity Research
Charles ButlerD. Boral Capital LLC.